Bone and cancer: the osteoncology

被引:42
作者
Ibrahim, Toni [1 ]
Mercatali, Laura [1 ,2 ]
Amadori, Dino [1 ]
机构
[1] IRCCS, Osteoncol & Rare Tumors Ctr, Meldola, Italy
[2] IRCCS, IRST, Biosci, Meldola, Italy
关键词
bone cancer; bone metastases; CTIBL;
D O I
10.11138/ccmbm/2013.10.2.121
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In recent years clinicians have witnessed a radical change in the relationship between bone and cancer, with in particular an increase in bone metastases incidence due to an improvement of patients survival. Bone metastases are responsible for the high morbidity in cancer patients with a strong clinical impact. For all these reasons, efforts have been directed to this important field with the foundation of the osteoncology, a new scientific and clinical branch involved in the management of patients with bone cancer disease, including primary bone tumors and bone metastases. Another innovative and important osteoncology topic is the Cancer Treatment Induced Bone Loss (CTIBL) that is mainly caused by antitu-moral treatment with bone resorption induction. The diagnostic and therapeutic options are described briefly in order to highlight the importance of the multi-disciplinary approach in this new field.
引用
收藏
页码:121 / 123
页数:3
相关论文
共 22 条
[1]  
Berenson JR, 1996, NEW ENGL J MED, V335, P1785
[2]   Antiresorptive therapies in oncology and their effects on cancer progression [J].
Bundred, Nigel .
CANCER TREATMENT REVIEWS, 2012, 38 (06) :776-786
[3]   Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2 [J].
Chakrabarti, Rumela ;
Hwang, Julie ;
Blanco, Mario Andres ;
Wei, Yong ;
Lukacisin, Martin ;
Romano, Rose-Anne ;
Smalley, Kirsten ;
Liu, Song ;
Yang, Qifeng ;
Ibrahim, Toni ;
Mercatali, Laura ;
Amadori, Dino ;
Haffty, Bruce G. ;
Sinha, Satrajit ;
Kang, Yibin .
NATURE CELL BIOLOGY, 2012, 14 (11) :1212-+
[4]   Risks and benefits of bisphosphonates [J].
Coleman, R. E. .
BRITISH JOURNAL OF CANCER, 2008, 98 (11) :1736-1740
[5]   Clinical course and prognostic factors following bone recurrence from breast cancer [J].
Coleman, RE ;
Smith, P ;
Rubens, RD .
BRITISH JOURNAL OF CANCER, 1998, 77 (02) :336-340
[6]  
Frassoldati A., 2010, OSTEONCOLOGY TXB, P456
[7]  
Guise TA, 1998, ENDOCR REV, P1918
[8]   Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases [J].
Hortobagyi, GN ;
Theriault, RL ;
Porter, L ;
Blayney, D ;
Lipton, A ;
Sinoff, C ;
Wheeler, H ;
Simeone, JF ;
Seaman, J ;
Knight, RD ;
Heffernan, M ;
Reitsma, DJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (24) :1785-1791
[9]  
Ibrahim T, 2013, TUMORI IN PRESS
[10]   Role of RANK, RANKL, OPG, and CXCR4 Tissue Markers in Predicting Bone Metastases in Breast Cancer Patients [J].
Ibrahim, Toni ;
Sacanna, Emanuele ;
Gaudio, Michele ;
Mercatali, Laura ;
Scarpi, Emanuela ;
Zoli, Wainer ;
Serra, Patrizia ;
Ricci, Rossana ;
Serra, Luigi ;
Kang, Yibin ;
Amadori, Dino .
CLINICAL BREAST CANCER, 2011, 11 (06) :369-375